Novo Nordisk A/S (NYSE:NVO) is listed among the 10 Best European Stocks to Buy According to Analysts. On April 17, Citigroup Inc. lowered the firm’s price target on Novo Nordisk A/S (NYSE:NVO) to DKK 275 from DKK 309 while maintaining a Neutral rating on the shares. Although the target was reduced, the continued coverage reflects ongoing institutional focus on one of the global leaders in diabetes and obesity treatment. The same day, market data reported mixed options sentiment in Novo Nordisk A/S (NYSE ...